Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

Patients treated at the initial dose in an ongoing Phase Ib trial demonstrated a 2.5 log10 median viral load decline after three days

Conference Call Today at 8:30AM EST

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced results from the first cohort of an ongoing Phase Ib clinical trial of ANA598, the Company's investigational non-nucleoside polymerase inhibitor. ANA598 was very well-tolerated and demonstrated potent antiviral activity in patients infected with chronic Hepatitis C virus (HCV) in this first cohort of the study.

Patients in the first cohort received 200 mg ANA598 (n=8) or placebo (n=2), twice-daily (bid) for three days. At the end of the treatment period, the median viral load decline was 2.5 log10 (>99%), with a range of 1.4-3.4 log10, for the eight patients who received ANA598. Three patients who received ANA598 were genotype 1a and demonstrated a median viral load decline of 1.6 log10, while five patients who received ANA598 were genotype 1b and demonstrated a median viral load decline of 2.6 log10. All eight patients who received ANA598 demonstrated a rapid decline in viral load, and no patients demonstrated viral rebound while on study drug. In addition to the robust viral load decline, ANA598 was very well-tolerated and there were no serious adverse events in the first dose cohort, although conclusions regarding longer-term safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. Patients are currently being enrolled in the second cohort (400 mg bid) of the study. Anadys expects to report detailed data from multiple cohorts of the study at an upcoming medical conference.

"We are very pleased with the antiviral activity and safety of ANA598
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... WOODBRIDGE, ON , April 30, 2015 /PRNewswire/ ... a specialty pharmaceutical company with a focus on ... health, announced its operational highlights and financial results ...  All dollar amounts referenced herein are in Canadian ... in 2014 have been significant, with the right ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
(Date:4/30/2015)... Calif. , April 30, 2015  IRIDEX Corporation ... release its first quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, May ... quarter and other business developments. Interested parties ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
... ProStrakan Group plc (LSE: PSK) today announced the ... the first rapidly-disintegrating tablet placed under the tongue for ... (F.D.A.) approved ABSTRAL, an opioid analgesic, in January 2011 ... patients, 18 years of age or older, ...
... Daiichi Sankyo, Inc. (DSI) announced today that John P. ... Effective today, Mr. Gargiulo succeeds Joseph P. Pieroni who is ... the past 14 years. "John,s experiences within ... him well for his new role and responsibility," said Joseph ...
Cached Medicine Technology:ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 2ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 3ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 4ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 5ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 6ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 7John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. 2
(Date:5/2/2015)... NY (PRWEB) May 02, 2015 It’s ... a deadly natural disaster strikes anywhere on this planet, ... leverage human sympathy and compassion for their own personal ... States Computer Emergency Readiness Team) issued an alert ... “of potential email scams citing the earthquake in Nepal. ...
(Date:5/2/2015)... On Tuesday April 7th, the patient care ... celebrate improvements in patient care. In 2014 the hospital, ... zero acquired ventilator associated infections, zero central line associated ... also recently named a Top Performer by the Joint ... the teamwork of staff from all departments involved in ...
(Date:5/2/2015)... May 02, 2015 ZoomCare, the Portland-based ... submitted plans to offer its new healthcare insurance to ... ZOOM+ Personal Health Insurance System is the nation’s first ... enhance human performance. ZOOM+ Personal Health Insurance was ZoomCare’s ... system that are subject to review and regulation by ...
(Date:5/1/2015)... 02, 2015 The Venetian on Grace ... http://www.thevenetiangracebay.com , and it is elegant and sophisticated, like ... and attractive turquoise hues of Grace Bay Beach. ... percent of leisure travelers used their smartphones throughout the ... used in the planning and researching and continued through ...
(Date:5/1/2015)... Royal River Natural Foods, a locally-owned independent ... new study that found two natural nutrients, glucosamine and ... function as well as standard drug treatment after six ... , The report is part of the May 2015 ... which Royal River Natural Foods publishes for free each ...
Breaking Medicine News(10 mins):Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2
... and 40s to have children, they are more willing ... capitalize on their remaining childbearing years, according to new ... Austin. Such "reproduction expediting" includes one-night stands ... In a paper published in the July edition of ...
... in the door of the sports industry, your race may ... a new study from North Carolina State University that examined ... research has shown that management positions in the sports industry ... a prejudice against blacks in managerial positions exists because of ...
... Wednesday, July 7, 2010 In an effort to extend ... from Wake Forest University Baptist Medical Center are partnering with ... international trial ever sponsored by the US National Institute on ... the Elderly (ASPREE) study aims to assess whether aspirin can ...
... News) -- Cosmetic contact lenses that give wearers an ... trend among teenagers and young adults," the American Academy ... The "circle" lens extends beyond the iris and, in ... among the young increased recently after pop star Lady ...
... Reporter , TUESDAY, July 6 (HealthDay News) -- The popular ... chronic lower back pain caused by osteoarthritis, a new study ... against glucosamine, with other recent studies showing similar results. ... pain for a long time (more than 6 months), will ...
... of scientists and health professionals from the field of ... the American Association of Physicists in Medicine (AAPM) from ... will present the latest technological advances in medical imaging ... issues facing the field today. AAPM is ...
Cached Medicine News:Health News:Ticking biological clock increases women's libido, new research shows 2Health News:Study shows race, not experience, impacts hiring in sports world 2Health News:Can aspirin prolong a healthy life? 2Health News:Lady Gaga-Inspired Lens Fad Draws Warning From Eye Docs 2Health News: Glucosamine Ineffective for Lower Back Pain Linked to Arthritis 2Health News: Glucosamine Ineffective for Lower Back Pain Linked to Arthritis 3
The TS100-F trinocular model comes with a photo port that accepts Nikon's FX-III series photomicrographic systems, CCTV camera, or digital camera....
... A standard laboratory microscope whose ... imagery combine to make it ... E400 is designed to fit ... the user to fit the ...
... incorporate the slight change in the difficulty ... letters derived from the best corrected visual ... ETDRS study. The original charts difficulty scores ... eyes. In addition to the revised arrangement ...
Created to simplify stereopsis screening in children. Based on principles of random dots. No glasses are necessary for this stereo test, and the child's eye movement can be easily observed....
Medicine Products: